Chong Kun Dang gears up on first generic of ‘Revlimid’ recording KRW 7 trillion

Chong Kun Dang was approved to conduct bioequivalent tests for approval of the first generic of ‘Revlimid(generic name: lenalidomide, Celgene),’ a multiple myeloma therapy whose substance patent will be expired next year.

Revlimid recorded approximately USD 6 billion sales in the global market. It is a blockbuster drug which expects to make approximately USD 8 billion(KRW 9.5 trillion) prescri...